Article
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews.
American journal of human genetics - 1 Oct 2002
Rennert Hanna, Bercovich Dani, Hubert Ayala, Abeliovich Dvora, Rozovsky Uri, Bar-Shira Anat, Soloviov Sonya, Schreiber Letizia, Matzkin Haim, Rennert Gad, Kadouri Luna, Peretz Tamar, Yaron Yuval, Orr-Urtreger Avi
Abstract excerpt
HPC1/RNASEL was recently identified as a candidate gene for hereditary prostate cancer. We identified a novel founder frameshift mutation in RNASEL, 471delAAAG, in Ashkenazi Jews. The mutation frequency in the Ashkenazi population, estimated on the basis of the frequency in 150 healthy young women, was 4% (95% confidence interval [CI] 1.9%-8.4%). Among Ashkenazi Jews, the mutation frequency was higher in patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.